XILIS, Inc. services

Xilis’ rapid and scalable patient-derived MicroOrganoSphere (MOS) technology platform enhances precision medicine and pharmaceutical drug discovery and development. Compared to conventional patient-derived models, MOS provides faster, higher-throughput, and greater cost savings, as well as more predictive and accurate results. MOS can be used in large-scale pharmacogenomic studies that are representative of the breadth of human genetic diversity during pre-clinical development. We believe the technology not only has the potential to make research more cost efficient, but also significantly more effective.